"Exploring Immunotherapy Combinations For The Treatment Of HCC" - Anita T. Shaffer
Novel immunotherapy combinations are currently under investigation for the treatment of patients with hepatocellular carcinoma (HCC), with several promising phase III trials incorporating checkpoint inhibitors now underway. Finding successful ways to combine these therapies is among the most significant trends emerging as part of the next wave of discovery in the field, according to experts. Josep M. Llovet, MD, PhD, director and founder of The Liver Cancer Program and professor of medicine at the Icahn School of Medicine at Mount Sinai, said he expects the focus of investigative efforts moving forward to be on developing frontline therapies that demonstrate superiority over the current options. “I don’t see the field moving to third-line design,” said Dr. Llovet. “It has been estimated that only 40 percent of the patients who receive frontline therapy are suitable for second-line.” Even fewer patients then become eligible for third-line treatment, he said.
- Josep M. Llovet, MD, PhD, Director, Founder, The Liver Cancer Program, Professor, Medicine, Icahn School of Medicine at Mount Sinai